Amgen to present 19 abstracts including Repatha data at ACC 16

Amgen announced this week that it will present 19 abstracts associated with its cardiovascular portfolio that will include new data from the evaluation of Repatha (evolocumab) at the American College of Cardiology’s 65th Annual Scientific Session (ACC 16).

The evaluation of Repatha was in patients who have high cholesterol yet are unable to tolerate statins.

Repatha is a human monoclonal antibody that hinders proprotein convertase subtilisin/kexin type 9 (PCSK9), which is a protein that decreases the liver’s capability to discard low-density liproprotein cholesterol (LDL-C), also known as bad cholesterol, from the blood.

Included in the 19 abstracts that will be presented by Amgen are a Late-Breaking Clinical Trial presentation of the GAUSS-3 (Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3) Phase 3 trial conducted with patients with high cholesterol levels who are unable to tolerate statins, and an oral presentation that will examine the safety of very low levels of LDL-C in patients taking Repatha.

Also among the presentations given by Amgen will be a worldwide health economics study that explored LDL-C levels in patients with high cardiovascular disease risk who were on lipid-lowering therapies in real-world populations.

The ACC 16 will take place in Chicago on April 2-4.